explore -WSS

explore

author：comprehensive 2025-10-01 15:39:04 - browse：825

Adam Feuerstein, upper left, moderated a panel with, clockwise, David Chang of Allogene Therapeutics, Rachel Haurwitz of Caribou Biosciences, and Lynelle Hoch of Bristol Myers Squibb. STAT

If you ask biopharma leaders what’s ahead for CAR-T cancer therapy, they say the future is bright. And that future will also look markedly different than it does today, three of them said at the STAT 2023 Future Summit on Wednesday.

Now in its second decade, the cell therapy — which attacks cancer by extracting white blood cells from a patient, genetically modifying them, and then re-infusing them to fight the cancer — has made remarkable strides. Biotech reporter Adam Feuerstein reminded panelists that Emily Whitehead, the first pediatric patient to receive the therapy at age 10, has just started college.

But for all its success in changing the lives of up to 7,000 patients to the point one can use the word “cure,” the field has been hampered by wait lists at manufacturers making these patient-specific, autologous therapies and a shortage of medical centers to administer them. Patients bear a burden, too: Training their B cells to attack their tumors requires an onerous depletion process before their cells can be taken out of their bodies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Judge denies Trump's request for new trial in E. Jean Carroll case

explore

leisure time

WSS

In rare move, senator releases unverified FBI source report alleging Biden bribe

Scientists grapple with ethics of stem cell research

Appeals court upholds Josh Duggar's conviction for downloading child sex abuse images

South Korea begins evacuating thousands of Scouts from coastal campsite as tropical storm nears

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

Tesla CFO Zachary Kirkhorn steps down, but will remain with company through year's end

leisure time

explore

hotspot

The cancer drug shortage isn’t new — and neither are the solutions

The stock market has soared this year, but will it last? Experts weigh in

The high cost of giving birth even with insurance

In rare move, senator releases unverified FBI source report alleging Biden bribe

Cancer drug shortages should be causing more outrage

Arizona Democrat to raise extreme heat with Biden 1 year out from Senate primary

Novavax promises a turnaround & Lilly roils the obesity market

Appeals court upholds Josh Duggar's conviction for downloading child sex abuse images

As demand for Covid shots wanes, Moderna seeks its next success

Stanford president’s abrupt resignation sparks debate

leisure time

How a Boston hospital is priming medical residents to use GPT

After a decade, new Gardasil ad campaign gets it (mostly) right

Illinois to ban advertising for guns allegedly marketed to kids and militants

South Korea begins evacuating thousands of Scouts from coastal campsite as tropical storm nears

Delta passengers in Vegas fall sick while waiting on flight in triple

Israel demolishes home of alleged Palestinian attacker, fueling West Bank tensions

entertainment

explore

leisure time

focus